Clinical trials: Myotonia
Neuromuscular Disease, Malignant Hyperthermia
The Prevalence of RYR1-related Disease
The skeletal muscle ryanodine receptor (RYR1) gene encodes an important calcium channel in skeletal muscle, with an important role in muscle contraction. Mutations (i.e.
- Conditions
- Neuromuscular Disease, Malignant Hyperthermia, Congenital Myopathy, Multiminicore Disease
- Trial name
- NCT06791369
- Where
- United Kingdom
- Volunteers
- 2,000 people
- Sponsor
- King's College London
Myopathy, Muscular Dystrophies
Muscle Health Measurements Using Electrical Impedance Myography
This study is being done to further develop a device, the mScan, to measure muscle health as compared to measurements of muscle health using MRI (magnetic resonance imaging).
- Conditions
- Myopathy, Muscular Dystrophies, Myositis, Myofibrillar Myopathy
- Trial name
- NCT07502989
- Testing
- Electrical Impedance Myography
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
Paramyotonia Congenita, Nondystrophic Myotonia
Using MRI in Patients With Non-dystrophic Myotonia to Access Muscle Contractility
The aim of this project is (1) to investigate whether or not structural muscle abnormalities could be a consequence of the disorder and (2) to provide further clinical description of this rare phenotype.
- Trial name
- NCT04808388
- Testing
- MRI
- Where
- Denmark
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Central Core Disease, Multi-Minicore Disease
The Natural History and Muscle Fatigability of Patients With Congenital Myopathies.
Core myopathies (CCD/MmD), nemaline myopathies (NEM) and centronuclear myopathies (CNM) are three types of rare congenital myopathies.
- Conditions
- Central Core Disease, Multi-Minicore Disease, Nemaline Myopathy, Centronuclear Myopathy
- Trial name
- READYCOM (NCT06157268)
- Testing
- Natural history and non therapeutical therapy
- Where
- 2 sites in Netherlands
- Volunteers
- 100 people
- Sponsor
- Radboud University Medical Center
Neuromuscular Diseases
Muscle Oxygenation in Effort in Neuromuscular Diseases
Previous studies showed modifications of muscle oxygenation parameters in muscular dystrophies du to an impairment or an absence of dystrophin.
- Trial name
- OXYNEMU (NCT02789059)
- Testing
- muscle oxygenation
- Where
- 3 sites in France
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- University Hospital, Lille
Phenotype, Genotype
Phenotype - Genotype Correlation in a Sample of Egyptian Patients With Congenital Myopathies and Congenital Muscular Dystrophies
The aim of this study is to correlate the phenotype and genotype among a sample of Egyptian patients with Congenital myopathies and Congenital muscular dystrophies.
- Conditions
- Phenotype, Genotype, Correction, Sample
- Trial name
- NCT07138963
- Testing
- Genetic Testing and Muscle Biopsy
- Where
- Egypt
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Ain Shams University
Myotonia, Non-Dystrophic Myotonia
Effectiveness of Mexiletine for Treating People With Non-Dystrophic Myotonia
Nondystrophic myotonias (NDM) are neuromuscular disorders caused by genetic abnormalities in certain muscle cell membrane proteins. The proteins affect muscle contraction.
- Trial name
- NCT00832000
- Testing
- Mexiletine
- Where
- 7 sites in United States, Canada and 2 more
- Volunteers
- 59 people
- Sponsor
- Richard Barohn, MD
Myotonia Congenita, Paramyotonia Congenita
Study of Ranolazine in Myotonia Congenita, Paramyotonia Congenita and Myotonic Dystrophy Type 1
The purpose of this study is to gather preliminary data to determine if ranolazine is a safe and effective treatment for the symptoms of myotonia congenital, paramyotonia congenita, and myotonic dystrophy type 1.
- Conditions
- Myotonia Congenita, Paramyotonia Congenita, Myotonic Dystrophy 1
- Trial name
- NCT02251457
- Testing
- Ranolazine
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Ohio State University
Myotonia
Cardiovascular Consequences of NIV Withdrawal in Patients With Myotonic Dystrophy
Background: Myotonic dystrophy lead to highly heterogeneous, multisystemic symptoms including myotonia, progressive muscle weakness, cardiac conduction defects, cataract, metabolic dysfunction, and excessive daytime somnolence.
- Trial name
- NCT00745238
- Testing
- withdrawal of non-invasive ventilation
- Where
- France
- Volunteers
- 35 people
- Sponsor
- University Hospital, Grenoble
Congenital Myotonic Dystrophy, Childhood Myotonic Dystrophy
Trial Readiness and Endpoint Assessment in Pediatric Myotonic Dystrophy Extension
This is a natural history study to improve the types of assessments and biological samples that will be used in clinical drug trials in both congenital myotonic dystrophy and childhood myotonic dystrophy.
- Conditions
- Congenital Myotonic Dystrophy, Childhood Myotonic Dystrophy, Myotonic Dystrophy
- Trial name
- TREAT-EXT (NCT06747884)
- Where
- 4 sites in United States, Brazil
- Volunteers
- 200 people
- Sponsor
- Virginia Commonwealth University
Central Core Disease, Centronuclear Myopathy
Molecular and Genetic Studies of Congenital Myopathies
In the Congenital Myopathy Research Program at Boston Children's Hospital and Harvard Medical School, the researchers are studying the congenital myopathies (neuromuscular diseases present from birth), including central core…
- Conditions
- Central Core Disease, Centronuclear Myopathy, Congenital Fiber Type Disproportion, Multiminicore Disease
- Trial name
- NCT00272883
- Where
- United States
- Volunteers
- 4,000 people
- Sponsor
- Boston Children's Hospital
Muscle Atrophy, Myotonia
Electromyostimulation (EMS) of Astronauts in Spaceflight (Easymotion-2)
This is a prospective spaceflight study involving an investigational non-risk device called the EasyMotionSkin for whole body electric muscle (myo) stimulation (WB-EMS) onboard the International Space Station (ISS).
- Conditions
- Muscle Atrophy, Myotonia, Stiffness; Spine, Exercise Overtraining
- Trial name
- Easymotion-2 (NCT06492057)
- Testing
- Electromyostimulation (EMS), Myoton, Electromyography (EMG)
- Where
- Germany
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Charite University, Berlin, Germany
Congenital Myotonic Dystrophy
Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy
This is an open-label phase 2/3 study for individuals with Congenital Myotonic Dystrophy (Congenital DM1) who participated in the preceding AMO-02-MD-2-003 study or individuals with either Congenital or Childhood Onset DM1 who…
- Trial name
- REACH CDM X (NCT05004129)
- Testing
- Tideglusib
- Where
- 14 sites in United States, Australia and 2 more
- Volunteers
- 76 people
- Sponsor
- AMO Pharma Limited
Congenital Myopathy, Neuromuscular Diseases
Changes of Motor Function Tests in Congenital Myopathy Subjects Treated With Oral Salbutamol as Compared to no Treatment
Congenital myopathies (CM) is a large group of muscle disorders, presenting with hypotonia and non-progressive generalised muscle weakness, which can lead to motor developmental delay.More than 20 genes can cause CM and currently…
- Conditions
- Congenital Myopathy, Neuromuscular Diseases, Musculoskeletal Diseases, Nemaline Myopathy
- Trial name
- COMPIS (NCT05099107)
- Testing
- Salbutamol (as Salbutamol Sulfate) 2 Mg Oral Tablet, Salbutamol Only Product in Oral Dose Form
- Where
- Sweden
- Volunteers
- 18 people
- Sponsor
- Vastra Gotaland Region
Non-Dystrophic Myotonia
MExiletine Versus Lamotrigine in Non-Dystrophic Myotonias
This is a clinical trial to determine if Lamotrigine is non-inferior to Mexiletine for the treatment of myotonia in patients with Non-Dystrophic Myotonia. Non-dystrophic Myotonia is a genetic condition for which there is no cure.
- Trial name
- MEND (NCT05017155)
- Testing
- Mexiletine, Lamotrigine 25Mg Oral Tablet, Extended Release
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- University College, London
Nemaline Myopathy
Nemaline Myopathy Clinical Research Network (NM-CTRN)
The goal of this study is to establish a research network to help define the natural disease history and clinical outcome measures for Nemaline Myopathy (NM).
- Trial name
- NCT06774703
- Where
- 6 sites in United States, Canada
- Volunteers
- 50 people
- Sponsor
- Stanford University
DM1, Myotonic Dystrophy
Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) Extension
Myotonic Dystrophy type 1 (DM1) is an autosomal dominant multisystemic disorder that causes progressive disability and shortened life expectancy.
- Conditions
- DM1, Myotonic Dystrophy, Myotonic Dystrophy 1, Myotonic Dystrophy Type 1
- Trial name
- END-EXT (NCT07700225)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Virginia Commonwealth University
Nondystrophic Myotonias, Myotonia Congenita
Characteristics of Nondystrophic Myotonias
Nondystrophic myotonias (NDM) are muscle disorders caused by genetic abnormalities in certain muscle cell membrane proteins. Individuals with NDM experience limited muscle relaxation, which causes pain, weakness, and impaired…
- Conditions
- Nondystrophic Myotonias, Myotonia Congenita, Myotonic Disorders
- Trial name
- NCT00244413
- Where
- 6 sites in United States, Canada and 1 more
- Volunteers
- 94 people
- Sponsor
- Richard Barohn, MD
Myotonia
An Open-Label, Randomized, Cross-Over Study to Investigate the Efficacy and Safety of Mexiletine PR Compared to Mexiletine IR
An Open-Label, Randomized, Cross-Over Study to Investigate the Efficacy and Safety of Mexiletine PR compared to Mexiletine IR in Patients with Non-Dystrophic Myotonias (ACHILLES study)
- Trial name
- NCT07097701
- Testing
- Granular powder in unit dose foil-lined sachet Mexiletine (PR), Oral Capsule Mexiletine (IR)
- Where
- Belgium
- Volunteers
- 24 people
- Sponsor
- Lupin Ltd.
Congenital Myotonic Dystrophy
Efficacy and Safety of Tideglusib in Congenital Myotonic Dystrophy
This is a randomized, multicenter, double-blind, placebo-controlled, Phase 2/3 study of patients (aged 6 to 16 years) diagnosed with Congenital Myotonic Dystrophy (Congenital DM1).
- Trial name
- NCT03692312
- Testing
- Tideglusib
- Where
- 14 sites in United States, Australia and 3 more
- Volunteers
- 56 people
- Sponsor
- AMO Pharma Limited